Epidemiology and healthcare resource utilization in inflammatory bowel disease in Colombia between 2017 and 2021: A retrospective claims database study.
{"title":"Epidemiology and healthcare resource utilization in inflammatory bowel disease in Colombia between 2017 and 2021: A retrospective claims database study.","authors":"Fabián Juliao-Baños, Viviana Parra-Izquierdo, Tatiana Pacheco-Páez, Janeth Tatiana Acosta Leaño","doi":"10.1016/j.gastrohep.2025.502532","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>The incidence and prevalence of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are increasing across Latin America. IBD has an important impact on patients' quality of life and is associated with significant healthcare resource utilization (HCRU). This study aimed to describe the more recent epidemiological characteristics and HCRU patterns of IBD in Colombia.</p><p><strong>Methods: </strong>Retrospective study using real-world data from the national claims database SISPRO (Sistema de Información para la Protección Social) between 2017 and 2021. The data considered were sociodemographic (sex and age), epidemiological (incidence, prevalence, and mortality), and HCRU data.</p><p><strong>Results: </strong>We identified 54,961 cases of prevalent ulcerative colitis (UC) and 13,136 cases of Crohn's disease (CD). Between 2017 and 2019, the incidence rates for UC increased from 3.82 to 5.18 per 100,000 individuals, while the incidence for CD rose from 0.48 to 0.83 per 100,000. The prevalence of these conditions reached its highest point in 2019, with UC at 48.65 and CD at 15.41 per 100,000 population. Mortality data indicated 259 deaths registered with UC and 77 with CD. The utilization of biologic therapies saw a significant rise from 2020 to 2021, particularly with anti-TNF agents being the most frequently prescribed. The patterns observed in outpatient visits and hospital admissions followed similar trajectories, exhibiting a downturn during the COVID-19 pandemic.</p><p><strong>Conclusions: </strong>This study examined the epidemiology, HCRU, and costs of IBD in Colombia using SISPRO data. Despite a decrease during the COVID-19 pandemic, the incidence and prevalence of IBD have increased over time, accompanied by elevated HCRU and medication costs. These insights could contribute to informed decision-making and resource allocation for enhanced patient care in Colombia.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502532"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterologia y hepatologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.gastrohep.2025.502532","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aims: The incidence and prevalence of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are increasing across Latin America. IBD has an important impact on patients' quality of life and is associated with significant healthcare resource utilization (HCRU). This study aimed to describe the more recent epidemiological characteristics and HCRU patterns of IBD in Colombia.
Methods: Retrospective study using real-world data from the national claims database SISPRO (Sistema de Información para la Protección Social) between 2017 and 2021. The data considered were sociodemographic (sex and age), epidemiological (incidence, prevalence, and mortality), and HCRU data.
Results: We identified 54,961 cases of prevalent ulcerative colitis (UC) and 13,136 cases of Crohn's disease (CD). Between 2017 and 2019, the incidence rates for UC increased from 3.82 to 5.18 per 100,000 individuals, while the incidence for CD rose from 0.48 to 0.83 per 100,000. The prevalence of these conditions reached its highest point in 2019, with UC at 48.65 and CD at 15.41 per 100,000 population. Mortality data indicated 259 deaths registered with UC and 77 with CD. The utilization of biologic therapies saw a significant rise from 2020 to 2021, particularly with anti-TNF agents being the most frequently prescribed. The patterns observed in outpatient visits and hospital admissions followed similar trajectories, exhibiting a downturn during the COVID-19 pandemic.
Conclusions: This study examined the epidemiology, HCRU, and costs of IBD in Colombia using SISPRO data. Despite a decrease during the COVID-19 pandemic, the incidence and prevalence of IBD have increased over time, accompanied by elevated HCRU and medication costs. These insights could contribute to informed decision-making and resource allocation for enhanced patient care in Colombia.
背景和目的：炎症性肠病（IBD）的发病率和患病率，包括克罗恩病（CD）和溃疡性结肠炎（UC），在拉丁美洲正在增加。IBD对患者的生活质量有重要影响，并与显著的医疗资源利用率（HCRU）相关。本研究旨在描述哥伦比亚IBD的最新流行病学特征和HCRU模式。方法：回顾性研究使用国家索赔数据库SISPRO (Sistema de Información para la Protección Social) 2017年至2021年的真实数据。考虑的数据包括社会人口学（性别和年龄）、流行病学（发病率、患病率和死亡率）和HCRU数据。结果：我们确定了54,961例普遍溃疡性结肠炎（UC）和13,136例克罗恩病（CD）。在2017年至2019年期间，UC的发病率从每10万人3.82例上升到5.18例，而CD的发病率从每10万人0.48例上升到0.83例。这些疾病的患病率在2019年达到最高点，UC为每10万人48.65人，CD为15.41人。死亡率数据显示，UC登记的死亡人数为259人，CD登记的死亡人数为77人。从2020年到2021年，生物疗法的使用率显著上升，特别是抗肿瘤坏死因子药物是最常用的处方。在门诊就诊和住院中观察到的模式遵循类似的轨迹，在COVID-19大流行期间表现出低迷。结论：本研究使用SISPRO数据调查了哥伦比亚IBD的流行病学、HCRU和费用。尽管在2019冠状病毒病大流行期间有所下降，但随着时间的推移，IBD的发病率和流行率有所增加，同时HCRU和药物费用也有所上升。这些见解有助于在哥伦比亚作出明智的决策和分配资源，以加强对病人的护理。
期刊介绍：
Gastroenterology and Hepatology is the first journal to cover the latest advances in pathology of the gastrointestinal tract, liver, pancreas, and bile ducts, making it an indispensable tool for gastroenterologists, hepatologists, internists and general practitioners.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
